Tempest licenses CD7-targeted in vivo CAR-T platform and secures additional capital
Tempest Therapeutics exclusively licensed Senlang's CD7-targeted platform and raised up to $50 million via an equity line of credit, propelling its in vivo CAR-T development in the competitive oncology market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed